Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Blood (2023) 142 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2023-178933

Published: 2023

Journal Articles

Frailty Impact on Outcomes of Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Anca Prica, Tiana Coley, Rachel Aitken, Abi Vijenthira, Manjula Maganti, Samantha J Mayo, John Kuruvilla, Michael Crump, Sita D. Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir MH Alibhai, Christine Chen

Blood (2023) 142 (Supplement 1): 3768.

https://doi.org/10.1182/blood-2023-189154

Published: 2023

Journal Articles

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Samantha J Mayo, Kim Edelstein, Lori Bernstein, Tiana Coley, Stacey Morrison, Abi Vijenthira, Manjula Maganti, John Kuruvilla, Michael Crump, Sita D. Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir MH Alibhai, Christine Chen, Anca Prica

Blood (2023) 142 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2023-190650

Published: 2023

Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Blood (2023) 142 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2023-186997

Published: 2023

Journal Articles

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Anup J Devasia, Sahar Khan, Eshetu Atenafu, Harjot Vohra, Frédéric Larose, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Christina Zeglinski, Zubaida Mohamed, Christine Chen

Blood (2023) 142 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2023-190310

Published: 2023

Journal Articles

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Sahar Khan, Salman Basrai, Donna Reece, Sita D. Bhella, Vishal Kukreti, Anca Prica, A. Keith Stewart, Suzanne Trudel, Harjot Vohra, Chloe Yang, Sagi Abelson, Christine Chen

Blood (2023) 142 (Supplement 1): 760.

https://doi.org/10.1182/blood-2023-190978

Published: 2023

Journal Articles

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

Alan M Williams, Ken L Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Amber Chang, Christine Chen, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Maksim Mamonkin, Raedun Clarke, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4547–4548.

https://doi.org/10.1182/blood-2022-167139

Published: 2022

Journal Articles

High-Density Cryopreservation of Off-the-Shelf CAR-NK Cells Facilitates On-demand Treatment Access

Ya-Ju Chang, Niancao Chen, Christine Chen, Tingxia Guo, Jaslem Herrera Valdez, Svetlana Gaidarova, Bryan Hancock, Betsy Rezner, Yvonne Lentz, Mark Plavsic, Richard Anderson, Raedun Clarke, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4693–4694.

https://doi.org/10.1182/blood-2022-162712

Published: 2022

Journal Articles

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Anup Joseph Devasia, Sahar Khan, Harminder K Paul, Frédéric Larose, Eshetu G. Atenafu, Donna E. Reece, Suzanne Trudel, A. Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Susan Jomah, Zubaida Mohamed, Christine Chen

Blood (2022) 140 (Supplement 1): 10043–10044.

https://doi.org/10.1182/blood-2022-170681

Published: 2022

Journal Articles

FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

John Reiser, Szeman Ruby Chan, Ketan Mathavan, David Sillitti, Cristina Mottershead, Bethany Mattson, Melissandre Pache, Alma Gutierrez, Whitney Scoon, Yanni Zhu, Andrew Gilder, Christine Chen, Kimberly Staquet, Michael Ports, Charles Drake, Joseph Erhardt, Ryan Bjordahl, Jode P. Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4560–4561.

https://doi.org/10.1182/blood-2022-170501

Published: 2022

Journal Articles

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Blood (2021) 138 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2021-146324

Published: 2021

Journal Articles

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Nizar J. Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, T. J. Unger, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Christine Chen

Blood (2018) 132 (24): 2546–2554.

https://doi.org/10.1182/blood-2018-06-858852

Published: 2018

Includes: Supplemental data

Journal Articles

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Christine Chen, David Siegel, Martin Gutierrez, Meagan Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Jesus G. Berdeja, Michael Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, T. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece

Blood (2018) 131 (8): 855–863.

https://doi.org/10.1182/blood-2017-08-797886

Published: 2018

Includes: Supplemental data

Journal Articles

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Blood (2018) 131 (3): 301–310.

https://doi.org/10.1182/blood-2017-07-795047

Published: 2018

Includes: Supplemental data

Journal Articles

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Abi Vijenthira, MD, Manjula Mangati, Michael Crump, MD, Vishal Kukreti, MD, John Kuruvilla, MD, Rodger Tiedemann, MD PhD, Christine Chen, MD, Anca Prica, MD

Blood (2016) 128 (22): 1795.

https://doi.org/10.1182/blood.V128.22.1795.1795

Published: 2016

Journal Articles

Final Analysis of Overall Survival from the First Trial

Blood (2016) 128 (22): 241.

https://doi.org/10.1182/blood.V128.22.241.241

Published: 2016

Journal Articles

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Anca Prica, MD, Vinita Dhir, Nuchanan Areethamsirikul, MD, Christine Chen, MD, Donna Reece, MD, Suzanne Trudel, MD, Rodger Tiedemann, MBChB, PhD, Vishal Kukreti, MD

Blood (2016) 128 (22): 1184.

https://doi.org/10.1182/blood.V128.22.1184.1184

Published: 2016

Journal Articles

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Blood (2016) 128 (22): 977.

https://doi.org/10.1182/blood.V128.22.977.977

Published: 2016

Journal Articles

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Blood (2016) 128 (22): 3330.

https://doi.org/10.1182/blood.V128.22.3330.3330

Published: 2016

Journal Articles

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Henry Siu Him Chan, MBChB, Madeline Phillips, Sophia Farooki, MD FRCPC, Giovanni Piza Rodriguez, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 3457.

https://doi.org/10.1182/blood.V128.22.3457.3457

Published: 2016

NARROW

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Frailty Impact on Outcomes of Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

High-Density Cryopreservation of Off-the-Shelf CAR-NK Cells Facilitates On-demand Treatment Access

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Final Analysis of Overall Survival from the First Trial

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only